drugset
drugset / Trial / NCT06444191

Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

NCT06444191 ↗

Phase 1 Completed 23 enrolled Principia Biopharma, a Sanofi Company
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single-dose and multiple doses study to assess the Pharmacokinetics (PK) of rilzabrutinib as well as to evaluate the tolerability of rilzabrutinib in Japanese and Caucasian Healthy Male and Female subjects.

Timeline

Start
2021-01-04
Primary completion
2021-04-12
Completion
2021-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilzabrutinib Small molecule — Oral

Indications

No indication recorded.